“Our collaboration with NanoMab provides Lantheus the opportunity to extend our diagnostic and radiopharmaceutical expertise into the fast growing market of immuno-oncology,” said Mary Anne Heino, President and Chief Executive Officer of Lantheus. “We already serve the oncology field with several radiopharmaceutical agents and are excited to work with NanoMab to bring the first broadly available PD-L1 imaging research tool to the global pharmaceutical community.”
“NanoMab is proud to partner with Lantheus for the development and the commercialization of NM-01, as we think our unique technology can help progress innovation in immuno-oncology,” said Ting Hong Hoi, CEO of NanoMab. “Lantheus has the infrastructure, established expertise and the reach to best optimize the value of NM-01 for patients and our shareholders.”
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
NM-01 is in Phase 1 clinical development with 21 patients currently enrolled in a study that will eventually recruit a total of 50 patients. The agent has a short half-life and provides diagnostically significant results in approximately two hours. Early Phase 1 study data was published in the February 22, 2019 issue of the Journal of Nuclear Medicine (Xing et al.). NanoMab plans to file an Investigational Medicinal Product Dossier (IMPD) in the United Kingdom in the second half of 2019.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada.
About NanoMab Technology Limited
NanoMab Technology Limited is a privately-held biopharmaceutical company focusing on the development of next generation radiopharmaceuticals for cancer precision medicine to address the unmet diagnostic and medical needs of cancer patients around the world. NanoMab’s goal is to develop a pipeline of theranostic couple camelid antibodies with its proprietary camelid antibodies platform to address the unmet diagnostic and medical need for cancer patients around the world.
Back to HCB News
